207 related articles for article (PubMed ID: 22687510)
1. Experimental central nervous system aspergillosis therapy: efficacy, drug levels and localization, immunohistopathology, and toxicity.
Clemons KV; Schwartz JA; Stevens DA
Antimicrob Agents Chemother; 2012 Aug; 56(8):4439-49. PubMed ID: 22687510
[TBL] [Abstract][Full Text] [Related]
2. Assessing the antifungal activity, pharmacokinetics, and tissue distribution of amphotericin B following the administration of Abelcet and AmBisome in combination with caspofungin to rats infected with Aspergillus fumigatus.
Wasan KM; Sivak O; Rosland M; Risovic V; Bartlett K
J Pharm Sci; 2007 Jul; 96(7):1737-47. PubMed ID: 17080414
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of Abelcet alone, or in combination therapy, against experimental central nervous system aspergillosis.
Clemons KV; Parmar R; Martinez M; Stevens DA
J Antimicrob Chemother; 2006 Aug; 58(2):466-9. PubMed ID: 16760192
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic and toxicologic studies in a murine model of invasive pulmonary aspergillosis.
Clemons KV; Schwartz JA; Stevens DA
Med Mycol; 2011 Nov; 49(8):834-47. PubMed ID: 21539507
[TBL] [Abstract][Full Text] [Related]
5. Comparative efficacies of conventional amphotericin b, liposomal amphotericin B (AmBisome), caspofungin, micafungin, and voriconazole alone and in combination against experimental murine central nervous system aspergillosis.
Clemons KV; Espiritu M; Parmar R; Stevens DA
Antimicrob Agents Chemother; 2005 Dec; 49(12):4867-75. PubMed ID: 16304147
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of Abelcet and caspofungin, alone or in combination, against CNS aspergillosis in a murine model.
Imai J; Singh G; Fernandez B; Clemons KV; Stevens DA
J Antimicrob Chemother; 2005 Jul; 56(1):166-71. PubMed ID: 15917284
[TBL] [Abstract][Full Text] [Related]
7. Assessing the antifungal activity and toxicity profile of amphotericin B lipid complex (ABLC; Abelcet) in combination with caspofungin in experimental systemic aspergillosis.
Sivak O; Bartlett K; Risovic V; Choo E; Marra F; Batty DS; Wasan KM
J Pharm Sci; 2004 Jun; 93(6):1382-9. PubMed ID: 15124198
[TBL] [Abstract][Full Text] [Related]
8. Assessment of efficacy of antifungals against Aspergillus fumigatus: value of real-time bioluminescence imaging.
Galiger C; Brock M; Jouvion G; Savers A; Parlato M; Ibrahim-Granet O
Antimicrob Agents Chemother; 2013 Jul; 57(7):3046-59. PubMed ID: 23587947
[TBL] [Abstract][Full Text] [Related]
9. Liposomal amphotericin B (AmBisome) reduces dissemination of infection as compared with amphotericin B deoxycholate (Fungizone) in a rate model of pulmonary aspergillosis.
Leenders AC; de Marie S; ten Kate MT; Bakker-Woudenberg IA; Verbrugh HA
J Antimicrob Chemother; 1996 Aug; 38(2):215-25. PubMed ID: 8877535
[TBL] [Abstract][Full Text] [Related]
10. Voriconazole brain tissue levels in rhinocerebral aspergillosis in a successfully treated young woman.
Elter T; Sieniawski M; Gossmann A; Wickenhauser C; Schröder U; Seifert H; Kuchta J; Burhenne J; Riedel KD; Fätkenheuer G; Cornely OA
Int J Antimicrob Agents; 2006 Sep; 28(3):262-5. PubMed ID: 16908120
[TBL] [Abstract][Full Text] [Related]
11. Long-term treatment of invasive sinus, tracheobroncheal, pulmonary and intracerebral aspergillosis in acute lymphoblastic leukaemia.
Björkholm M; Kalin M; Grane P; Celsing F
Infection; 2012 Feb; 40(1):81-5. PubMed ID: 21779887
[TBL] [Abstract][Full Text] [Related]
12. [Successful treatment of neuroaspergillosis in a patient with acute lymphoblastic leukemia: role of surgery, systemic antifungal therapy and intracavitary therapy].
Ozçelik T; Ozkalemkaş F; Kocaeli H; Altundal Y; Ener B; Ali R; Ozkocaman V; Hakyemez B; Tunali A
Mikrobiyol Bul; 2009 Jul; 43(3):499-506. PubMed ID: 19795628
[TBL] [Abstract][Full Text] [Related]
13. The effects of caspofungin and voriconazole in an experimental fungal infection of the ear due to Aspergillus.
Ayçiçek A; Cetinkaya Z; Kiyici H; Kenar F; Aşik G; Kiraz N
Eur Arch Otorhinolaryngol; 2009 Nov; 266(11):1703-9. PubMed ID: 19340446
[TBL] [Abstract][Full Text] [Related]
14. [Cerebral aspergillosis in an HIV-infected patient: unsuccessful outcome despite combined antifungal therapy. ].
Gasch O; Fernández N; Ayats J; Santin M
Enferm Infecc Microbiol Clin; 2009 Mar; 27(3):193-4. PubMed ID: 19306722
[No Abstract] [Full Text] [Related]
15. Phase-dependent antifungal activity against Aspergillus fumigatus developing multicellular filamentous biofilms.
Mowat E; Lang S; Williams C; McCulloch E; Jones B; Ramage G
J Antimicrob Chemother; 2008 Dec; 62(6):1281-4. PubMed ID: 18819968
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of caspofungin and voriconazole combinations in experimental aspergillosis.
MacCallum DM; Whyte JA; Odds FC
Antimicrob Agents Chemother; 2005 Sep; 49(9):3697-701. PubMed ID: 16127042
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the physicochemical, antifungal, and toxic properties of two liposomal amphotericin B products.
Olson JA; Adler-Moore JP; Jensen GM; Schwartz J; Dignani MC; Proffitt RT
Antimicrob Agents Chemother; 2008 Jan; 52(1):259-68. PubMed ID: 17967910
[TBL] [Abstract][Full Text] [Related]
18. Disseminated invasive aspergillosis with cerebral involvement successfully treated with caspofungin and voriconazole.
Gubler C; Wildi SM; Imhof A; Schneemann M; Müllhaupt B
Infection; 2007 Oct; 35(5):364-6. PubMed ID: 17721739
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of caspofungin alone and in combination with voriconazole in a Guinea pig model of invasive aspergillosis.
Kirkpatrick WR; Perea S; Coco BJ; Patterson TF
Antimicrob Agents Chemother; 2002 Aug; 46(8):2564-8. PubMed ID: 12121933
[TBL] [Abstract][Full Text] [Related]
20. Pharmacodynamic effects of simulated standard doses of antifungal drugs against Aspergillus species in a new in vitro pharmacokinetic/pharmacodynamic model.
Meletiadis J; Al-Saigh R; Velegraki A; Walsh TJ; Roilides E; Zerva L
Antimicrob Agents Chemother; 2012 Jan; 56(1):403-10. PubMed ID: 22064546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]